Benzbromarone

For research use only. Not for therapeutic Use.

  • CAT Number: A000947
  • CAS Number: 3562-84-3
  • Molecular Formula: C17H12Br2O3
  • Molecular Weight: 424.10
  • Purity: ≥95%
Inquiry Now

Benzbromarone(Cat No.:A000947)is a potent uricosuric agent used primarily to treat gout by reducing uric acid levels in the blood. It works by inhibiting the reabsorption of urate in the kidneys, promoting its excretion and thus preventing crystal formation in joints. Benzbromarone is especially effective for patients who cannot tolerate other uric acid-lowering therapies, such as allopurinol. Known for its rapid action and effectiveness in cases of hyperuricemia, Benzbromarone offers an alternative treatment for managing chronic gout and related metabolic conditions, enhancing patients’ quality of life.


Catalog Number A000947
CAS Number 3562-84-3
Synonyms

3562-84-3; Benzbromaron; Desuric; Urinorm; Normurat

Molecular Formula C17H12Br2O3
Purity ≥95%
Storage -20°C
IUPAC Name (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone
InChI InChI=1S/C17H12Br2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3
InChIKey WHQCHUCQKNIQEC-UHFFFAOYSA-N
SMILES CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br
Reference

1: Chou HW, Chiu HT, Tsai CW, Ting IW, Yeh HC, Huang HC, Kuo CC; CMUH Kidney
Research Group. Comparative effectiveness of allopurinol, febuxostat and
benzbromarone on renal function in chronic kidney disease patients with
hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2017
Nov 17. doi: 10.1093/ndt/gfx313. [Epub ahead of print] PubMed PMID: 29165620.

<br>
2: He L, Li C, Liu X, Yang Q, Zhang H, Xu W, Zhang L, Liu C. Comparative study on
the interaction between 3 CYP2C9 allelic isoforms and benzbromarone by using
LC-MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Dec
1;1070:97-103. doi: 10.1016/j.jchromb.2017.10.051. PubMed PMID: 29100760.
<br>

3: Wang H, Peng Y, Zhang T, Lan Q, Zhao H, Wang W, Zhao Y, Wang X, Pang J, Wang
S, Zheng J. Metabolic Epoxidation Is a Critical Step for the Development of
Benzbromarone-Induced Hepatotoxicity. Drug Metab Dispos. 2017
Dec;45(12):1354-1363. doi: 10.1124/dmd.117.077818. Epub 2017 Oct 11. PubMed PMID:
29021351.
<br>

4: Nicola&#239; J, Thevelin L, Bing Q, Stieger B, Chanteux H, Augustijns P, Annaert P.
Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux
Transporter in the Hepatocellular Disposition of Vincristine. Pharm Res. 2017
Nov;34(11):2336-2348. doi: 10.1007/s11095-017-2241-0. Epub 2017 Aug 21. PubMed
PMID: 28828541.
<br>

5: Yoshida M, Cho N, Akita H, Kobayashi K. Association of a reactive intermediate
derived from 1/’,6-dihydroxy metabolite with benzbromarone-induced hepatotoxicity.
J Biochem Mol Toxicol. 2017 Oct;31(10). doi: 10.1002/jbt.21946. Epub 2017 Jun 9.
PubMed PMID: 28598529.
<br>

6: Lin HC, Daimon M, Wang CH, Ho Y, Uang YS, Chiang SJ, Wang LH. Allopurinol,
benzbromarone and risk of coronary heart disease in gout patients: A
population-based study. Int J Cardiol. 2017 Apr 15;233:85-90. doi:
10.1016/j.ijcard.2017.02.013. Epub 2017 Feb 13. PubMed PMID: 28202260.
<br>

7: Cho N, Kobayashi K, Yoshida M, Kogure N, Takayama H, Chiba K. Identification
of novel glutathione adducts of benzbromarone in human liver microsomes. Drug
Metab Pharmacokinet. 2017 Feb;32(1):46-52. doi: 10.1016/j.dmpk.2016.10.412. Epub
2016 Oct 27. PubMed PMID: 28131653.
<br>

8: Wang H, Feng Y, Wang Q, Guo X, Huang W, Peng Y, Zheng J. Cysteine-Based
Protein Adduction by Epoxide-Derived Metabolite(s) of Benzbromarone. Chem Res
Toxicol. 2016 Dec 19;29(12):2145-2152. Epub 2016 Dec 1. PubMed PMID: 27989145.
<br>

9: Zhou Q, Su J, Zhou T, Tian J, Chen X, Zhu J. A study comparing the safety and
efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients:
a retrospective cohort study&#8233;. Int J Clin Pharmacol Ther. 2017 Feb;55(2):163-168.
doi: 10.5414/CP202629. PubMed PMID: 27936522.
<br>

10: Kojima S, Kojima S, Hifumi A, Soejima H, Ogawa H. Therapeutic strategy for
efficient reduction of serum uric acid levels with allopurinol versus
benzbromarone in hyperuricemic patients with essential hypertension – A
randomized crossover study (terao study). Int J Cardiol. 2016 Dec 1;224:437-439.
doi: 10.1016/j.ijcard.2016.09.073. Epub 2016 Sep 24. PubMed PMID: 27701062.

Request a Quote